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Abstract: Gene-activated matrix (GAM)-based therapeutics for tissue regeneration are limited 
by efficacy, the lack of spatiotemporal control and availability of target cells, all of which 
impact negatively on their translation to the clinic. Here we describe an advanced ultrasound-
responsive GAM containing target cells that facilitates matrix-assisted sonoporation (MAS) to 
induce osteogenic differentiation. Ultrasound-responsive GAMs consisting of fibrin/collagen 
hybrid-matrices containing microbubbles, bone morphogenetic protein BMP2/7 co-expression 
plasmids together with C2C12 cells were treated with ultrasound either in vitro or following 
parenteral intramuscular implantation in vivo. Using direct measurement for alkaline 
phosphatase activity, von Kossa staining and immuno-histochemical analysis for osteocalcin 
expression, MAS-stimulated osteogenic differentiation was confirmed in the GAMs in vitro 7 
days after treatment with ultrasound. At day 30 post-treatment with ultrasound, ectopic 
osteogenic differentiation was confirmed in vivo using X-ray microcomputed tomography 
(µCT) and histological analysis. Osteogenic differentiation was indicated by the presence of 
ectopic bone structures in all animals treated with MAS. In addition, bone volumes in this 
group were statistically greater than those in the control groups. This novel approach of 
incorporating a MAS capability into GAMs could be exploited to facilitate ex vivo gene transfer 
with subsequent surgical implantation or alternatively provide a minimally invasive means of 
stimulating in situ transgene delivery for osteoinductive gene-based therapies. 
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1. Introduction 
Gene-activated matrices (GAMs) are smart biomaterials designed to deliver therapeutic genes 
in vivo in order to augment wound-healing by inducing a local niche of regeneration with 
appropriate transient differentiation cues produced by genetically modified precursor cells 
(Bonadio, 2000; Balmayor and van Griensven, 2015). Traditional GAMs usually consist of a 
natural biopolymer carrier matrix with the potential to support tissue regeneration as a scaffold, 
retain secreted factors in an extracellular matrix (ECM)-like microenvironment and provide 
therapeutic nucleic acids encoding a growth or differentiation factor that deliver the stimulus 
for tissue formation (Lu et al., 2013; Tierney et al., 2013).  Whilst GAM systems have been 
reported that use viral gene transfer approaches (Balmayor and van Griensven 2015;  Peterson 
et al., 2009), it has been suggested that GAMs employing non-viral strategies using episomal 
elements such as DNA plasmids are preferable because they deliver transient expression and 
incorporate less risk (Yin et al., 2014). Owing to their safety and low therapeutic cost profile, 
GAMs have been extensively investigated over the past 16 years. The breath of their potential 
clinical applications range is indicated by numerous studies that have successfully 
demonstrated their experimental use in bone regeneration (Lu et al., 2013), cartilage 
regeneration (Kayabashi et al., 2013), osteochondral regeneration (Schillinger et al., 2008), 
wound healing (Michlits et al., 2007) and cardiac and neuro-regeneration (Gonzales et al., 
2006). Despite these exciting reports, very few GAM-based approaches have been clinically 
tested and this is due, at least in part, to the traditionally low gene delivery efficacies provided 
by non-viral gene transfer modalities (Ramamooth and Narvekar, 2015). The high doses of 
nucleic acid necessitated by low gene transfer efficacy and the resulting potential of transgene 
persistence or dispersion at off-target sites in vivo, has significantly impaired the development 
of this technology (Jafari et al., 2012; Wang et al., 2013). A clear un-met need therefore exists 
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in this area for approaches that can safely provide effective and controlled delivery of 
transgenes to target cells in 3D environments in situ.  
Many approaches have been developed over the years to enhance gene transfer 
efficiencies in GAMs and some of these have yielded promising results (Tierney et al., 2013; 
Wang et al., 2015).  However, the use of approaches that are unlicensed for human use or 
remain untested in 3D matrices hinders accelerated straightforward translation to the clinic 
(Yin et al., 2014). In addition, the lack of in situ spatiotemporal control on gene transfer and 
expression in existing GAM designs provides another significant challenge to their widespread 
clinical use as a controlled regenerative modality (Tierney et al., 2013).  
Ultrasound-mediated, microbubble-enhanced gene delivery is a minimally invasive, 
physical gene transfer modality, which has been shown to promote intracellular delivery of 
nucleic acid in vitro and in vivo (Escoffre et al., 2013).   In addition, the use of ultrasound 
together with microbubbles to enhance cellular uptake of therapeutic agents has an excellent 
safety profile (Lammertink et al., 2015). The above attributes would therefore suggest that 
ultrasound-mediated microbubble-enhanced gene transfer could provide an ideal means of 
remotely controlling gene transfer events within GAMs. With this end in mind, our group 
recently demonstrated that ultrasound-mediated, microbubble-enhanced gene delivery could 
be achieved with target cells embedded in fibrin/collagen hydrogel matrices in vitro (Nomikou 
et al., 2016). In associated studies we were also able to demonstrate that should it prove 
necessary, an additional level of control at the transcriptional level could be incorporated into 
our expression plasmids to enable tight control of the therapeutic transgene expression window 
after delivery by ultrasound-mediated, microbubble-enhanced gene transfer (Feichtinger et al., 
2014).  
On the basis of the above studies, we hypothesized that a MAS-based approach could 
be used to initiate osteogenic differentiation in a GAM for use in osteoinductive gene therapy. 
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Here we describe an ultrasound-responsive GAM consisting of a fibrin/collagen hydrogel 
matrix incorporating C2C12 cells as a surrogate osteogenic progenitor target, polymeric 
microbubbles, together with constitutive and inducible therapeutic plasmid DNA capable of 
co-expressing bone morphogenic proteins 2 and 7 (BMP2/7). We demonstrate that it can be 
used to enable osteogenic differentiation in vitro and demonstrate that it can be employed to 
provide enhanced ectopic bone formation in response to site-directed, exposure to externally 
applied ultrasound in vivo. The ability to non-invasively initiate osteogenic differentiation 
suggests this ultrasound-responsive GAM could provide a novel means of controlling gene-
based therapies in regenerative medicine.  
 
2. Materials and Methods  
2.1. Plasmid DNA and cell culture 
The inducible and constitutive single-vector BMP2/7 co-expression plasmids, pTetON-
BMP2/7 and pVAX1-BMP2/ 7 have been described previously (Feichtinger et al. 2014). The 
reporter plasmid pCMV-Luc, encoding the firefly luciferase gene under the control of the CMV 
promoter, was supplied by PlasmidFactory GmbH & Co (Germany). C2C12 mouse myoblast 
precursor cells were obtained from in-house stocks and used as both an in vitro and a matrix-
implanted in vivo target for gene transfer and expression in 3D matrices. The cell line was 
maintained in high glucose-containing tissue culture medium (Dulbecco's modified Eagle's 
medium; DMEM) supplemented with glutamine (GibcoBRL, UK) and 5% (v/v) fetal bovine 
serum (Life Technologies, UK) at 37°C in a 5% CO2 humidified atmosphere. When required, 
single cell suspensions were prepared by treating cell monolayers with a 0.05% (w/v) solution 
of trypsin containing 0.02% (w/v) EDTA in phosphate-buffered saline (PBS). Cells were 
subsequently harvested and washed in Opti-MEM reduced serum medium by centrifugation 
prior to use. 
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2.2. Preparation of microbubbles 
Polymeric microbubbles were prepared as described previously (McEwan et al., 2014). 
Microbubbles were stored as a freeze-dried preparation and prior to use were reconstituted with 
PBS, followed by several washes by centrifugation in order to remove the polymeric debris. 
After each wash microbubbles were recovered from the surface of the suspension using a 
pipette. The microbubble suspension was diluted in PBS when necessary. 
 
2.3. Preparation of cell-containing 3D matrices for matrix-assisted sonoporation (MAS) 
 
Figure 1.  
 
3D matrices containing target cells were prepared as described previously (Nomikou et al., 
2016) except that a 15 µL aliquot of polymeric microbubble suspension replaced lipid-shelled 
microbubbles and the pCMV-Luc plasmid was replaced with the therapeutic plasmids 
described above. Unless otherwise stated, each 80µL aliquot of matrix contained 4 × 105 cells, 
together with microbubbles at a concentration of 108 microbubbles/ml and plasmid DNA at a 
concentration of 80 µg/mL (resulting in 6.4 µg total DNA dose per construct). For matrices in 
the absence of microbubbles and DNA, the suspension/solution was replaced by PBS and Opti-
MEM, respectively. For in vitro experiments, the mixture was left to gel for 10–15 s at room 
temperature. For in vivo experiments, the mixture was injected into the hind leg muscle of nude 
mice before gelation occurred using an insulin syringe.  
 
2.4. MAS-mediated gene transfer & osteogenic differentiation in vitro  
For in vitro experimentation, after each matrix had gelled, each well was treated with 
ultrasound, as described previously (Nomikou et al., 2016), using an SP100 sonoporator 
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(Sonidel Ltd., Ireland) emitting ultrasound at a frequency of 1 MHz. The transducer had an 
effective radiating area of 0.8 cm2. Samples were treated at a power density of 4 W/cm2 (spatial 
average:temporal peak; SATP) using a 25% duty cycle (pulse frequency 100 Hz), for 30 s 
(providing an energy density of 30 J/cm2 per treatment). Matrices were treated by placing the 
ultrasound transducer underneath the corresponding well. Contact between the multi-well plate 
and the transducer was mediated by ultrasound gel.  Following ultrasound treatment, a 150 µL 
aliquot of Opti-MEM was added to each well and the plates were placed in a humidified 5% 
CO2 atmosphere at 37°C for 1 h.  Each matrix was then transferred to a well of a 24-well plate 
with 2 mL of high glucose-containing DMEM supplemented with glutamine (GibcoBRL, UK) 
and 5% (v/v) foetal bovine serum and plates were incubated at 37°C in a humidified 5% CO2 
atmosphere. Every 48 h, the medium in the matrix-containing wells was renewed. 2 μL of 
doxycycline solution (1000ng/µL) was also added to the incubation medium of the matrices 
containing the pTetON-BMP2/7 inducible construct, once every 48 h.  
 
2.4.1. Bioluminescence imaging based quantification of gene transfer in vitro  
Bioluminescent imaging was used to assess ultrasound-mediated gene transfer using the 
luciferase-encoding reporter plasmid, pCMV-Luc as described previously (Nomikou et al., 
2016). Bioluminescence was recorded after 20 min, using a Xenogen IVIS® Lumina imaging 
system supported by Living Image® software v. 2.60. Using this software, each well was 
marked as a region of interest (ROI) and luciferase activity was expressed as photons emitted/s 
from each well.  
 
2.4.2. Alkaline phosphatase (ALP) assay for osteogenic differentiation in vitro  
Alkaline phosphatase production was employed as an osteogenic differentiation marker in 
GAMs and its production in matrices was determined 7 days post-treatment. Each matrix was 
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immersed in 300 μL of a 10 mg/mL p-nitrophenyl phosphate solution in ALP buffer (0.5 M 2-
amino-2-methyl-1-propanol, 2 mM magnesium chloride, pH 10.3) and incubated at 37°C for 
60 minutes. The reaction was terminated by the addition of 50 μL of NaOH to a final 
concentration of 0.2 M in each sample. The absorbance at 405 nm was determined using a 
VersaMax microplate reader (Molecular Devices, USA) and the activity of ALP delivered by 
the non-lysed clots was expressed as nmoles of p-nitrophenol (pNP) released per minute for 
each clot. For subsequent histological analyses, matrices were fixed and stored in absolute 
ethanol.  
 
2.4.3. Measurement of cell viability in 3D matrices 
Cell viability in 3D matrices was determined using the method described previously (Nomikou 
et al., 2016) and was based on an increase in fluorescence as a result of the cleavage of 
fluorescein diacetate (Fda) by esterase activity in viable cells. The fluorescence intensity of 
each matrix was measured using a FLUOstar Omega microplate reader (BMG Labtech, 
Germany), an excitation wavelength of 485 nm and an emission wavelength of 520 nm. Since 
this protocol was non-destructive, repeated measurement of cell viability was possible if the 
excess fluorescein was removed. When necessary, this was accomplished by washing twice 
under sterile conditions with medium (30 min/rinse) and subsequent incubation in a humidified 
5% CO2 atmosphere at 37°C until required for further analysis.  Cell viability rate (CVR) is a 
relative term defined by CVR = Ftn/Ft0, where Ftn is the fluorescence detected at a defined 
time point post embedding cells in matrices and Ft0 is the fluorescence detected immediately 
after embedding cells in matrices. 
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2.4.4. Histological analysis of matrices from in vitro studies 
Von Kossa staining was used to detect calcium deposits within treated matrices. Following 
fixation in ethanol as described above, matrices were embedded in paraffin wax and 5 µm thick 
serial sections were prepared using a microtome (Leica). Positive controls for osteogenic 
differentiation contained 300 ng of recombinant BMP2 (Induct OS® recombinant CHO-
derived human BMP2, Pfizer GmbH, Austria) per clot. The sections were then deparaffinised, 
hydrated in water and rinsed in several changes of distilled water. Sections were incubated in 
a 1% (w/v) silver nitrate solution under ultraviolet light for up to 30 minutes followed by 
several rinses in distilled water. Unreacted silver stain was removed by incubating the slides 
for 5 minutes with sodium thiosulphate followed by multiple rinses in distilled water. Sections 
were then counterstained with nuclear fast red for 5 minutes, rinsed in distilled water before 
being dehydrated in absolute ethanol, cleared in xylene and mounted in DPX. Immuno-
histochemical analysis of matrices for osteocalcin expression was also performed on 5 µm thick 
alcohol-fixed paraffin sections. Endogenous peroxidase activity was blocked using 2% (v/v) 
hydrogen peroxide and chymotrypsin (Sigma) enzymatic antigen retrieval was carried out by 
incubating sections in a 0.1% (w/v) enzyme solution (pH 7.8) for 30 minutes. Samples were 
incubated overnight at 4°C with mouse osteocalcin-specific primary antibody (1:100 dilution; 
Abcam, UK) and staining was achieved using peroxidase conjugated secondary antibody as 
per the manufacturer’s protocol (EnVision Kit, Dako, UK). Nuclei were counter stained with 
haematoxylin. The stained sections were visualized using an Olympus BX50 microscope and 
imaged using NIS Elements BR software (Ver. 3.0).  
 
2.5. MAS-mediated gene transfer & osteogenesis in vivo  
All animals were treated humanely and in accordance with licensed procedures under the UK 
Animals (Scientific Procedures) Act 1986. Prior to injection of the matrix formulation and 
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ultrasound treatment, animals were anaesthetized by intraperitoneal injection of 
Hypnorm:Hypnovel. The cell-containing 3D matrices were prepared as described above 
(Section 2.3) and 80µL immediately injected into the hind leg muscle of nude mice 
(Hsd:Athymic Nude-Foxn1nu mice, Harlan Laboratories, UK) prior to gelation. Four minutes 
after injection, the area was treated with ultrasound for 60 s using an SP100 (Sonidel Ltd., 
Ireland) sonoporator at a frequency of 1 MHz, a power density of 4 W/cm2 (spatial 
average:temporal peak; SATP) and using a 50% duty cycle (pulse frequency 100 Hz). A 
conventional ultrasound gel was employed to ensure adequate contact between the ultrasound 
transducer surface and skin. Animals were sacrificed 30 days after treatment and the treated 
limbs were surgically recovered, fixed in 10% formalin for 48 h and subsequently stored in 
70% (v/v) ethanol.   In these experiments 4 limbs were treated per group and each group was 
treated with;  (A) matrix containing cells, microbubbles and DNA in the absence of ultrasound 
(GAM without ultrasound); (B) matrix plus cells and microbubbles without DNA and treated 
with ultrasound (GAM without DNA with ultrasound); (C) matrix containing cells, 
microbubbles, DNA and treated with ultrasound (GAM treated with ultrasound) and (D) 
microbubbles and DNA in the absence of cells and treated with ultrasound.  
 
2.5.1. Micro Computed Tomography (μCT) analysis of ectopic bone formation 
Images of target limbs were obtained using a SCANCO µCT 50 (70 kVp 17.2µm, ≥2100 HU) 
(SCANCO Medical, Switzerland). The measurements were performed using the SCANCO 
evaluation software on the µCT. A ROI was drawn which included the entire limb but excluded 
the endogenous limb bones. This ROI provided a threshold intensity level of 2100 HU to 
identify sites of higher x-ray absorption within the limb. Each of these sites was visually 
inspected to ensure that (i) no bone fragments had adhered to the skin during surgical recovery 
of the limb and (ii) image artefacts were not being identified as ectopic bone. Bone volume 
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(mm3) and bone mineral density (mg hydroxyapatite per cm3) were calculated using the 
instrumentation operating system.  
 
2.5.2. Histological analysis of tissues from in vivo studies 
Fixation was performed in 4% formalin, rinsed in water and transferred to 50 and 70% alcohol. 
After µCT samples were dehydrated completely by an increasing series of alcohol immersed 
prior to embedding into paraffin in the intermedium xylol for histological processing. Serial 
sections of 4µm were prepared using a rotatory microtome (HM 355S Microm) and dried 
overnight. After de-paraffinisation, sections were analysed using van Kossa staining for 
mineralized material according to a standard protocol using Mayer’s haematoxylin as nuclear 
counter-stain. Positively stained areas were considered to be ectopic tissue if the location 
correlated with the anatomical location of granules identified in µCT scans, if they were located 
in the muscle or the associated connective tissue and if no sign of long bones (e.g. growth plate) 
was evident. 
 
2.6. Statistical analysis 
Statistical analysis of significance for in vitro data was conducted using ANOVA and normally 
distributed data groups were compared with the Tukey multiple comparison test (MCT), using 
GraphPad Prism 4.0. Unless stated otherwise, p < 0.05 was considered to indicate statistical 
significance. In vivo bone volumes and bone mineral densities were assumed to be normally 
distributed and therefore analysed by ANOVA and Newman Keuls post-test, accepting 
significance at p<0.05. 
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3. Results 
 
3.1. MAS-mediated gene transfer & osteogenic differentiation in vitro 
 
3.1.1. Bioluminescence imaging based quantification of gene transfer in vitro 
Prior to embarking on the osteogenic differentiation studies it was decided to confirm that the 
use of increased concentrations of the polymeric microbubbles together with increased 
concentrations of target cells within matrices would provide ultrasound-mediated gene transfer.  
To this end the pCMV-Luc plasmid encoding the luciferase reporter gene was used in matrices 
pre-loaded with target cells and microbubbles. The data (Figure 2A) demonstrated that, in the 
absence of ultrasound treatment, luciferase expression in matrices was low, whereas following 
treatment with ultrasound, expression of the reporter gene increased over 25-fold.  The data 
demonstrated that ultrasound-mediated gene transfer occurred in these new matrices using the 
polymeric microbubbles and using higher concentrations of target cells and microbubbles than 
those used previously (Nomikou et al., 2016).  When luciferase expression was examined at 
day 7 post application of ultrasound, it was noted that the level of gene expression had 
decreased (Figure 2A) and this confirmed that expression of the transgene was transient using 
this system.   
 
Figure 2.  
 
3.1.2. Measurement of cell viability in 3D matrices 
Since higher concentrations of target cells and microbubbles were employed in matrices in the 
current studies and in the presence of an ultrasonic field this could potentially have a deleterious 
effect on target cells, it was also decided to examine the effect of ultrasound treatment on cell 
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viability within matrices. Matrices were treated with ultrasound conditions used to effect gene 
transfer and cell viability was determined at 24 h, 48 h and 120 h after treatment. Cell viability 
in control matrices that had not been treated with ultrasound was also determined for 
comparative purposes. Results shown in Figure 2B demonstrate that C2C12 cells remained 
viable and proliferated over time, even at the high cell and microbubble concentrations used 
and these data served to further validate the use of the polymeric microbubbles in matrices.  
 
3.1.3. MAS-mediated induction of osteogenic differentiation in vitro 
 
3.1.3.1. Alkaline phosphatase activity 
Having demonstrated that ultrasound could be used to facilitate gene transfer and expression 
in 3D matrices without any negative impact on cell viability using high cell numbers with the 
new polymeric microbubbles, it was decided to use the approach to enable gene transfer of 
therapeutic plasmids co-expressing BMP2 and BMP7 into C2C12 cells and determine whether 
or not this would result in osteogenic differentiation. To this end, the effect of microbubbles 
and ultrasound on the delivery of the BMP2/7-co-expressing plasmid constructs (Feichtinger 
et al., 2014) (either pTetON-BMP2/7 or pVAX1-BMP2/7) and resultant osteogenic 
differentiation was examined in 3D matrices containing C2C12 cells. Where the inducible 
pTetON-BMP2/7 plasmid was used, the inducer doxycycline was added to the system. 
Ultrasound was used at a power density of 4 W/cm2, using a 25% duty cycle and samples were 
treated for 30s. Alkaline phosphatase was used as an endpoint for osteogenic differentiation 
and when it was determined in the 3D matrices 7 days post-treatment the results shown in 
Figure 2C and D were obtained. The data clearly demonstrate that for both constitutive 
expression plasmid pVAX-BMP2/7-containing matrices (Figure 2C) and the doxycycline 
inducible expression plasmid (pTetON-BMP2/7)-containing matrices (Figure 2D) with 
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incorporated microbubbles and treated with ultrasound (MAS treated), alkaline phosphatase 
activity was significantly higher than the corresponding control systems. In particular, for the 
pVAX-BMP2/7 system, in matrices that were not exposed to ultrasound and in matrices treated 
with ultrasound in the absence of microbubbles, alkaline phosphatase activity was 2.4- and 2.2-
fold lower, respectively, than the MAS-treated samples. For the pTetON-BMP2/7 system, in 
matrices that were not irradiated with ultrasound and in matrices treated with ultrasound in the 
absence of microbubbles, alkaline phosphatase activity was 2.7- and 2.4-fold lower, 
respectively, than the MAS-treated samples. In addition, when matrices containing the 
pTetON-BMP2/7 inducible plasmid in the absence of the inducer doxycycline were treated 
with MAS, alkaline phosphatase activity was similarly low. The latter result confirms that the 
increase in alkaline phosphatase activity detected in MAS-treated samples resulted from MAS-
specific gene transfer events.   It also demonstrates tight control of therapeutic transgene 
expression at the transcriptional level by doxycycline after MAS, where its addition to matrices 
led to a 1.5-fold increase in alkaline phosphatase activity over that obtained with the system 
employing the constitutive plasmid (pVAX1-BMP2/7) (Figure 2C, D).  
 
3.1.3.2. Histological examination of matrices from in vitro studies 
In addition to using the measurement of alkaline phosphatase expression at day 7 as a marker 
of osteogenic differentiation, the latter was confirmed by histological analysis for bone 
mineralisation and osteocalcin expression at day 14 post treatment.  To this end von Kossa 
staining for mineralisation and immuno-histochemical staining for osteocalcin were carried out 
on matrices harvested at day 14 post ultrasound treatment. Positive control matrices were 
generated by incorporation of 300 ng of recombinant BMP2 growth factor into C2C12-
containing matrices.   In qualitatively examining areas of interest within stained sections of the 
positive control, successful induction of osteogenic differentiation was suggested by the 
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presence of strongly positive mineral deposition (black specks) and more intense osteocalcin 
staining present (Figure 3-A1). Cells in MAS treated constructs without BMP2/7 co-expression 
plasmids or recombinant BMP2 treatment did not show mineral deposits or osteocalcin staining 
(Figure 3-A2). Qualitatively constructs containing the constitutive co-expression system 
pVAX-BMP2/7 and treated with MAS provided the most intense staining for mineralisation 
and osteocalcin (Figure 3-B1) when compared with control samples in the absence of 
ultrasound or treated with ultrasound in the absence of microbubbles (Figure 3-B2, B3 
respectively). The highest overall staining was observed in MAS treated matrices containing 
the inducible pTetON-BMP2/7 system in the presence of doxycycline (Figure 3-C1). Staining 
of the doxycycline induced control matrices in the absence of ultrasound (Figure 3-C3) or 
treated with ultrasound in the absence of microbubbles (Figure 3-C4) suggested low-level 
differentiation when compared with MAS treated samples.   For clarity, higher resolution 
images of selected sections are provided in Figure 3 D, E and F. 
 
 
Figure 3.  
 
3. 2. MAS-mediated gene transfer & osteogenesis in vivo 
Since the above findings suggested that ultrasound could be employed to facilitate osteogenic 
differentiation in a GAM harbouring a suitable recipient progenitor cell model in vitro, it was 
felt that it could provide an alternative to ex vivo gene-based therapies (Balmayor and van 
Griensven, 2015) for bone repair. Therefore, in subsequent experiments the liquid GAM was 
injected into the hindlimb muscle of recipient mice before it had gelled and osteogenesis was 
probed using µCT and histological analyses.  
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3.2.1. Micro Computed Tomography (μCT) analysis of ectopic bone formation 
The data obtained from µCT analysis are shown in Figure 4 and demonstrate positive ectopic 
bone formation in: 4 out of 4 (100%) limbs in group treated with the complete GAM an 
ultrasound (Figure 4C); 2 out of 4 (50%) limbs in the passive, GAM-mediated gene delivery 
control group without ultrasound treatment (Figure 4A) and 3 out of 4 (75%) limbs in the 
ultrasound treated, standard sonoporation control group without exogenous cells (Figure 4D). 
When the matrices including cells were delivered to control limbs without the plasmid, only 
one limb was found to contain minute amounts of ectopic bone (Figure 4 B).   Analysis of total 
bone volumes achieved per treatment site/animal revealed that MAS-mediated osteogenic gene 
delivery leads to a significant increase of formed bone volumes (Figure 4E) compared to all 
other groups (5.7-fold increase compared to passive, GAM-mediated delivery and 16.44-fold 
compared to standard sonoporation under current conditions), clearly demonstrating the 
therapeutic advantage of the novel approach over current non-viral gene delivery methods.   
Bone mineral densities (BMD) of new ectopic bone ranged from 750 to 1040 mg 
hydroxyapatite/cm3 of analysed bone volume with no significant differences amongst groups 
examined.  
 
Figure 4:  
 
3.2.2. Histological analysis of tissues from in vivo studies 
Histological examination of µCT positive MAS-treated samples confirmed mineralised 
nodules at ectopic sites in muscles by von Kossa staining (Figure 5A-C). Morphologically, the 
MAS-induced ectopic intramuscular bone structures exhibited a complex architecture 
including compact bone, structures with a bone marrow cavity with cells appearing like 
haematopoietic bone marrow and in some cases, even cartilage-like formations (Figure 5 B).  
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Figure 5.  
4. Discussion 
 
4.1. MAS-mediated gene transfer & osteogenic differentiation in vitro 
The efficacy of ultrasound in combination with microbubbles for in situ gene transfer in 3D 
matrices has been recently demonstrated by our group in vitro (Nomikou et al., 2016). In that 
study, the myoblast precursor cell line C2C12 was embedded in fibrin/collagen-based matrices 
containing ultrasound-responsive lipid-shelled microbubbles and a luciferase-expressing 
plasmid (pCMV-Luc). Since the ultrasound-responsive fibrin/collagen-based matrices 
employed in those studies could be formulated as a liquid, combined with suitable target cells 
and subsequently administered by injection before gelation, it was felt, that it presented an ideal 
tool for use in minimally-invasive tissue regenerative GAM-based approaches.   However, if 
the system was to be employed for such purposes it would be necessary to demonstrate that 
ultrasound-stimulated gene transfer within matrices could provide levels of gene expression by 
embedded target cells that would be sufficient to induce differentiation of those cells within 
the administered hydrogel.   In realising such an outcome, it was decided to modify the original 
matrix by incorporating more stable polymeric microbubbles that would persist within the 
matric for longer periods of time (McEwan et al., 2014).   In our previous study we used 
cationic microbubbles to maximise interaction between nucleic acid, microbubbles and target 
cells so that this would, in turn, enhance ultrasound-mediated gene transfer (Nomikou et al., 
2016). Therefore, to enhance interaction between the polymeric microbubbles and the target 
cells within matrices, it was decided to use both at concentrations that were higher than those 
used in our previous study (Nomikou et al., 2016) since this approach was shown to provide 
the same benefit afforded using cationic microbubbles (Nomikou et al., 2012).  The results 
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obtained served to validate our use of the more stable polymeric microbubbles in the GAM for 
MAS-based gene transfer. Apart from clearly demonstrating an improvement of gene transfer 
by MAS without impacting negatively on target cell viability within matrices, the data in Figure 
2 also demonstrate that gene expression in the ultrasound-treated system dropped almost 7-fold 
after 7 days.  Demonstrating transient expression of the transgene could prove very useful from 
a temporal control perspective in bone regeneration because it has been shown that a number 
of genes are transiently expressed during osteogenic differentiation and bone regeneration 
(Javed et al., 2010).   It could also be advantageous from a safety perspective because it could 
preclude many of the adverse effects associated with high therapeutic levels of BMP (Hustedt 
and Blizzard, 2014).     
Cell differentiation studies clearly demonstrated that MAS-mediated delivery of both 
the constitutive and inducible BMP2/7 expression systems led to a significant increase in 
osteogenesis as evidenced by quantitative ALP data and qualitative histological evaluation 
when compared with controls.  Controls exhibited low-level differentiation as indicated by the 
expression of ALP without ultrasound-stimulation, which may have resulted from passive gene 
delivery.   In the current study we demonstrate a 2.7-fold increase in ALP following treatment 
with ultrasound.  Using lipofection to transfer separate plasmids encoding BMP2 and BMP7 
into C2C12 cells, Kawai et al (2006) demonstrated a 7-fold increase in ALP.  However, in the 
latter case the target cells were not embedded in a matrix.  In overall terms, the alkaline 
phosphatase data, taken together with the histological analyses clearly demonstrate that MAS 
treatment in vitro facilitates stimulus-responsive gene transfer into the GAM-embedded target 
cell population (C2C12 cells) that is sufficient to drive osteogenic differentiation. The data 
essentially demonstrate that it is possible to control gene transfer-dependent osteogenic 
differentiation within GAMs in vitro using an external stimulus. The data obtained with the 
TetON system also suggest that additional control of transgene expression and subsequent 
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osteogenic differentiation can be incorporated into the novel GAM by judiciously manipulating 
control of expression of therapeutic nucleic acid constructs that would respond to inducers in 
vivo at a molecular genetic level as shown in previous work (Feichtinger et al., 2014a).  
 
4. 2. MAS-mediated gene transfer & osteogenesis in vivo 
In order to confirm the therapeutic potential offered by our approach it was decided to examine 
its ability to generate ectopic bone in murine muscle in vivo.  The pVAX-BMP2/7 plasmid was 
used here since it would be more appropriate for future clinical translation and would not be 
reliant on an the addition of an exogenous inducer. Use of this plasmid would also preclude 
any inducer-mediated effects so that osteoinduction would be the sole result of therapeutic gene 
transfer following the exposure to ultrasound. One of the major advantages of this GAM is that 
it is formulated as a liquid to enable injection into a chosen site and the fibrin gelling time may 
be adjusted to facilitate gelling directly post injection prior to activation.   Being able to 
accomplish this offers the advantage of retaining the therapeutic entity (osteogenic progenitor 
cells and therapeutic nucleic acids) at the desired site thereby minimising off-target bone 
generation.  It could also potentially allow the intraoperative preparation of a therapeutic gene 
therapy formulation (Evans and Hurd, 2015) if primary cell sources such as bone marrow or 
liposuction aspirates were available. In contrast to the in vitro prepared GAM of this study and 
other examples of so-called ‘gene plugs’ (Pascher et al., 2004), where gene transfer is carried 
out extracorporeally and the matrix is then press-fit into the defect area, the current approach 
could facilitate moulding of the injectable liquid matrix into a defect and allow post 
implantation gene transfer events.  Essentially the GAM could be compatible with either ex 
vivo gene transfer and subsequent surgical implantation as indicted by the in vitro data above 
or with surgical implantation followed by in vivo gene transfer.  The in vivo ectopic bone 
formation data obtained above suggest that this GAM could play a role in approaches involving 
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the latter.    The data demonstrated that the highest frequency of bone formation (100%) was 
delivered with MAS and this is in line with previous studies showing that sonoporation can 
significantly increase the frequency of successful gene delivery and associated bone formation 
in vivo (Feichtinger et al., 2014). The novel outcome of the current study regarding the 
significantly (5.4- to 16.4-fold) increased yields of bone volumes attainable with MAS (Figure 
4) compared to all other standard treatment modalities (passive GAM and sonoporation) is 
furthermore superior to those from previous studies by us and other groups in which multiple 
rounds of sonoporation and higher DNA doses were necessary for tissue formation (Feichtinger 
et al., 2014; Osawa et al., 2009). In our previous studies using a cell and matrix-free 
sonoporation-based approach it was necessary to use 100 µg of DNA and an ultrasound energy 
density of 90-600 J/cm2 whereas here we used 6.5 µg of DNA and an ultrasound energy density 
of 30 J/cm2 (Feichtinger et al., 2014). Thus, the current study provided bone formation in all 
limbs treated with a single MAS treatment and used much lower overall DNA and ultrasound 
doses. Being able to employ lower quantities of therapeutic nucleic acid could have important 
benefits in terms of precluding non-specific gene transfer events that could lead to off-target 
bone formation.    
It should also be noted that BMD values observed for ectopic structures were higher 
than those observed in previous studies using standard sonoporation alone (250 mg HA/cm3 at 
28 days) (Feichtinger et al., 2014) and ranged between reported values for cancellous (250-650 
mg HA/cm3) and cortical bone (1050-1250 mg HA/cm3) in mice (Entezari et al., 2012). 
Although the formation of complex ectopic bone structures with a stem cell niche has 
previously been demonstrated in multiple in vivo gene therapy studies including our own using 
BMPs as therapeutic genes (Osawa et al., 2010), the appearance of a cartilage-bone interface 
as observed in one sample in this study is interesting (Figure 5B). There are also indications in 
the literature that C2C12 cells specifically respond to certain BMP signalling cues which might 
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be present in the current setup and thus, the chosen therapeutic gene combination and 
administered target cell type might be the determinant of the observed cartilage formation in 
the present study. It has been shown that C2C12 cells can respond to BMP4 and differentiate 
down the chondrogenic lineage and can form ectopic bone and cartilage in vivo (Li et al., 2005). 
Interestingly, the BMP2/7 expression strategy used in the current study has been shown by 
others to specifically induce expression of BMP4 after BMP2/7 gene transfer in vivo (Kawai 
et al., 2006). Therefore, it might be possible that BMP2/7 expression resulted in endogenous 
BMP4 expression, which in turn can induce chondrogenic differentiation of C2C12 cells in 
vivo and result in the observed morphologically complex ectopic structures (Figure 5B). 
Although more appropriate staining procedures could be employed to confirm our observations 
relating to the presence of cartilage and bone marrow-like structures, this could represent a 
specific effect linked to the responsiveness of the exogenously-added cells in the current study 
and might explain the difference between previous in vivo gene therapy studies without cells 
in the GAM, indicating an additional level of control of tissue formation in the current setup 
by incorporation of certain specific progenitor cells into the GAM for MAS.   
 The MAS approach devised in this study could be developed for translation to human 
patients using clinically relevant mesenchymal stem cell sources (Alhadlaq,2004) such as 
adipose derived stem cells, bone marrow derived mesenchymal stem cells or any other source 
of autologous adult, expression capable somatic cells that can be harvested intra-operatively in 
a one-step intervention (Gafni et al., 2004) to enable straightforward translation. As the 
proposed strategy is reliant on the in situ expression of sufficient amounts of BMP, which can 
also act as a chemotactic cue for endogenous stem cells to home to the defect (Zhang et al., 
2014), the abundance, ease of harvesting and receptiveness to transgene delivery and 
expression of any target cell population is more important for the approach than the 
differentiation capabilities of the cells themselves, which are mainly required to act as drug 
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production/delivery vehicles in the current approach. Nevertheless, if expression capable and 
differentiation capable mesenchymal stem cells are to be used in any future translation of the 
MAS approach, therapeutic efficacy might be improved by combining both synergistic 
properties of the target cell population, enhancing therapeutic efficacy and potentially 
compensating for limited transfection efficacy.  The next stages in the preclinical development 
of the therapeutic MAS-based approach presented in the current work would therefore involve 
incorporation of a clinically relevant somatic cell source together with evaluation of the therapy 
in an appropriate preclinical orthotopic bone regeneration model.   Subsequent studies would 
also include an assessment of the quality of the resulting bone formed within the chosen model 
defect to allow for mechanical testing. 
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Figure Legends 
Figure 1 
Schematic representation of the matrix-assisted sonoporation (MAS) approach together with 
a light micrograph showing the gene activated matrix (GAM) components. Scale bar in right 
hand image represents 50μm. 
 
Figure 2 
Ultrasound-mediated gene transfer and differentiation in vitro. A. Luciferase expression 
(bioluminescence) by C2C12 embedded in the GAM and in the presence (+US) or absence (-
US) of ultrasound on day 1 and day 7 post-treatment where n=3, and error bars represent + 
SEM. B. Viability of C2C12 cells embedded in the GAM in the presence (+US) and absence 
(-US) at 24, 48 and 120 h post-treatment where n=3 and error bars represent + SEM and *: 
p<0.05. Alkaline phosphatase activity in GAMs containing the constitutive plasmid pVAX1-
BMP2/ 7 (C) and inducible plasmid pTetON-BMP2/7 (D) 7 days post-treatment; in the absence 
of ultrasound and presence of microbubbles (No US/MB); in the presence of ultrasound and 
absence of microbubbles (US/No MBs); with the complete matrix-assisted sonoporation 
protocol (MAS); in the absence of the inducer doxycycline (MAS/No Dox) and with MAS in 
the presence of doxycycline (MAS with Dox). In all cases except for No US/MB (n=2) n = 3 
and error bars represent + SEM (*: p<0.05, **: p<0.01). 
 
Figure 3 
 
Histological staining of GAMs treated in vitro. Sections were stained using von Kossa (upper 
panels A – C with cellular counterstain in red and mineralisation in black) and osteocalcin 
immunochemical staining (Lower panels A – C with cellular counterstain in blue and 
osteocalcin staining in brown). Row A shows sections of the positive control consisting of 
GAMs incorporating 300 ng BMP2 per construct (A1) and those of the negative control (A2) 
in the absence of therapeutic plasmid DNA or growth factor. Row B shows sections from 
GAMs containing the constitutive plasmid, pVAX-BMP2/7 treated with MAS (B1), GAMs in 
the absence of ultrasound (B2) and ultrasound treatment of the GAM without microbubbles 
(B3). Row C shows sections from GAMs containing the inducible plasmid pTetON-BMP-2/7 
treated with MAS in the presence of doxycycline (C1), GAMs treated with MAS in the absence 
of doxycycline (C2), GAMs treated with doxycycline without ultrasound (C3) and GAMs 
treated with doxycycline and ultrasound in the absence of microbubbles. Scale bars represent 
100 µm.   High resolution images of von Kossa- (left panel) and osteocalcin-stained (right 
panel) sections from GAMs treated with 300ng recombinant human BMP2 (D), GAMs 
containing the constitutive plasmid, pVAX-BMP2/7 and treated with MAS (E) and GAMs 
containing the inducible plasmid pTetON-BMP2/7 treated with MAS in the presence of the 
inducer doxycycline (F). Arrows highlight mineralisation positive and osteocalcin positive 
areas. Scale bars represent 100 µm 
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Figure 4 
Micro-computed tomography (µCT) scans and analysis of ectopic bone generated in vivo. (A) 
Images of limbs treated with the GAM without ultrasound.  (B) Images of limbs treated with 
the GAM without DNA and with ultrasound.  (C) Images of limbs treated with the complete 
GAM and ultrasound. (D) Images of limbs treated with microbubbles, DNA and ultrasound in 
the absence of the cells.  Ectopic bone structures are highlighted with red circles and scale bars 
represent 5 mm.   Bone volume analysis in mm3 (E) represented as scatter plots where error 
bars represent the mean + SEM. * p<0.05 and data were grouped to represent A, B, C and D in 
accordance with the µCT images above. 
 
Figure 5 
Histological analysis of sections from ectopic bone structures in limbs following MAS 
treatment and stained with von Kossa (black/brown) for mineralisation and nuclear counter 
staining using Meyer’s haematoxylin (blue). A: Ectopic bone structure showing bone marrow 
(*BM), bone (*B) and cartilage phase (*C) in surrounding muscle tissue (*M). Scale bar 
represent 200μm. B: Detail of tissue interface structure found in ectopic bone structure from 
(A), cartilage tissue including chondrocytes in lacunae (*C) is clearly seen interfacing with a 
subchondral bone phase (*B) and this osteochondral phase is covering a haematopoietic bone 
marrow phase (*BM) with visible erythrocytes. Scale bar represent 100μm. C: Ectopic bone 
structure showing bone marrow (*BM), bone (*B) and cartilage phase (*C) in surrounding 
muscle tissue (*M). Scale bar represent 100μm. 
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